Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
740 CHF | +0.41% | +4.37% | +8.66% |
Apr. 25 | EMS-Chemie Q1 Net Sales Decline | MT |
Feb. 14 | Bank Vontobel Lowers Price Target on EMS-Chemie, Maintains Hold Recommendation | MT |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- With an expected P/E ratio at 37.8 and 34.17 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.74% | 18.75B | C+ | ||
+13.43% | 64.32B | A- | ||
-3.69% | 45.95B | A- | ||
+13.69% | 39.61B | B+ | ||
+20.84% | 25.74B | A- | ||
-0.60% | 17.23B | B+ | ||
-21.03% | 15.86B | A- | ||
+1.01% | 15.03B | B+ | ||
-17.64% | 13.99B | C+ | ||
-23.90% | 13.09B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EMSN Stock
- Ratings EMS-CHEMIE HOLDING AG